{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06265220",
            "orgStudyIdInfo": {
                "id": "AB-101-03"
            },
            "organization": {
                "fullName": "Artiva Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Lupus",
            "officialTitle": "A Phase 1 Study to Evaluate the Effectiveness and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Kidney Involvement in Lupus or Other Forms of Refractory Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "ab-in-combination-with-b-cell-depleting-mab-in-patients-who-failed-treatment-for-class-iii-or-iv-lupus-nephritis-or-other-forms-of-refractory-lupus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-09",
            "studyFirstSubmitQcDate": "2024-02-15",
            "studyFirstPostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Artiva Biotherapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of \"natural killer\" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.\n\nThis clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus.\n\nThe primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus.\n\nPatients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status.\n\nPatients may receive up to 2 cycles of treatment spaced 24 weeks apart."
        },
        "conditionsModule": {
            "conditions": [
                "Lupus Nephritis - WHO Class III",
                "Lupus Nephritis - WHO Class IV",
                "Refractory Systemic Lupus Erythematosus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 51,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1: Dose confirmation of AB-101 as Monotherapy",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "Phase 1: Dose confirmation of AB-101 plus Rituximab combination",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Rituximab"
                    ]
                },
                {
                    "label": "Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: AB-101",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Obinutuzumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AB-101",
                    "description": "NK Cell Therapy",
                    "armGroupLabels": [
                        "Phase 1: Dose confirmation of AB-101 as Monotherapy",
                        "Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination",
                        "Phase 1: Dose confirmation of AB-101 plus Rituximab combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1: Dose confirmation of AB-101 as Monotherapy",
                        "Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination",
                        "Phase 1: Dose confirmation of AB-101 plus Rituximab combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lymphodepleting chemotherapy",
                    "armGroupLabels": [
                        "Phase 1: Dose confirmation of AB-101 as Monotherapy",
                        "Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination",
                        "Phase 1: Dose confirmation of AB-101 plus Rituximab combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Rituximab",
                    "description": "Anti-CD20 antibody therapy",
                    "armGroupLabels": [
                        "Phase 1: Dose confirmation of AB-101 plus Rituximab combination"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Obinutuzumab",
                    "description": "Anti-CD20 antibody therapy",
                    "armGroupLabels": [
                        "Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events",
                    "description": "Incidence, severity and causality of adverse events and serious adverse events",
                    "timeFrame": "From the time of consent through 104 weeks after initiation of study treatment"
                },
                {
                    "measure": "AB-101 Clinical Activity",
                    "description": "Determined by Overall Response Rate in subjects with lupus nephritis and refractory systemic lupus erythematosus",
                    "timeFrame": "From the time of first dose through 104 weeks after initiation of study treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria for Lupus Nephritis:\n\n* Adult subjects with biopsy proven lupus nephritis Class III or IV either with or without the presence of Class V according to the 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria, who failed or did not respond to previous standard of care treatment approaches\n* A kidney biopsy must be performed \\< 24 weeks prior to the screening visit or during the screening period.\n* Eligible subjects must have evidence of active disease on renal biopsy based on the modified NIH Lupus Nephritis activity and chronicity indices.\n* Eligible subjects must have detectable anti-double stranded DNA antibody titers for enrollment.\n\nInclusion Criteria for Refractory Systemic Lupus Erythematosus:\n\n* Diagnosis of SLE according to the 2019 EULAR/ACR Classification Criteria\n* Total SLE Disease Activity Index (SELENA-SLEDAI score) \\>8 sat screening\n* Failed at least 12 weeks of 2 conventional therapies for SLE\n\nExclusion Criteria:\n\n* Known past or current malignancy other than protocol stipulated low grade cancers, or curable cancer in complete response for \\>2 years\n* Known clinically significant cardiac disease\n* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE\n* Subjects with known active viral infections or, if with a history of HBV or HCV infections, have a viral load above the institution's limit of quantitation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AB-101-03 Study Team",
                    "role": "CONTACT",
                    "phone": "858-377-8306",
                    "email": "AB-101-03StudyTeam@ArtivaBio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sudhir Borgonha, MD",
                    "affiliation": "Artiva Biotherapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama at Birmingham (UAB)",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Megan Maier",
                            "role": "CONTACT",
                            "email": "mmaier@uabmc.edu"
                        },
                        {
                            "name": "Jose Rubio Mosquera, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "University of California, San Diego",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92121",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bosco Trinh",
                            "role": "CONTACT",
                            "email": "botrinh@health.ucsd.edu"
                        },
                        {
                            "name": "Bethany Karl, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009393",
                    "term": "Nephritis"
                },
                {
                    "id": "D000008181",
                    "term": "Lupus Nephritis"
                },
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005921",
                    "term": "Glomerulonephritis"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12338",
                    "name": "Nephritis",
                    "asFound": "Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11178",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9031",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "T3523",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2525",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069283",
                    "term": "Rituximab"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                },
                {
                    "id": "C000543332",
                    "term": "Obinutuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "asFound": "Infusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M288906",
                    "name": "Obinutuzumab",
                    "asFound": "Plate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}